febrile neutropenia

Related by string. Febrile neutropenia * Febrile : pyrexia mucositis sepsis febrile . febrile seizures . febrile seizure . febrile convulsions . febrile convulsion / Neutropenia : chemotherapy induced neutropenia . neutropenia thrombocytopenia . events thrombocytopenia neutropenia . thrombocytopenia neutropenia . severe neutropenia * neutropenia febrile neutropenia *

Related by context. All words. (Click for frequent words.) 77 leukopenia 77 neutropenia 75 thrombocytopenia 74 severe neutropenia 74 hematologic toxicity 73 lymphopenia 73 Neutropenia 72 neutropaenia 71 leucopenia 71 FluCAM arm 71 hematologic adverse 71 peripheral sensory neuropathy 70 hypophosphatemia 70 neutropenia dehydration dyspnea 70 gastrointestinal toxicities 70 fatigue asthenia 70 discontinuations due 70 infusion reactions 69 mucositis 69 5-FU/LV 69 4mg/kg 69 lopinavir r arm 69 ALT flares 68 thrombocytopenia neutropenia 68 myelosuppression 68 laboratory abnormalities 68 FOLFOX4 68 Infusion Reactions Severe 68 neutropenic fever 68 stomatitis 67 recurrent VTE 67 nasopharyngitis 67 tumor lysis syndrome 67 hypomagnesemia 67 non metastatic osteosarcoma 67 chlorambucil 67 achieved ACR# 67 fluorouracil 67 nephrotoxicity 67 neutropenia thrombocytopenia 67 mycophenolate mofetil 67 arterial thromboembolic events 67 receiving VICTRELIS 67 Toxicities 67 trimethoprim sulfamethoxazole 67 PREZISTA r arm 67 â ‰ ¥ 67 events AEs 67 thromboembolic events 67 endophthalmitis 67 FOLFIRI alone 67 mitoxantrone 67 incidence ≥ 67 hypercalcemia 67 REYATAZ r arm 67 neutropenic 67 oral allopurinol 66 plus gemcitabine 66 severe oral mucositis 66 FOLFOX 66 treatment emergent adverse 66 Febrile neutropenia 66 peripheral edema 66 Flu Cy 66 DOXIL 66 pyrexia mucositis sepsis febrile 66 Fludara 66 ACTEMRA TM 66 comparator arm 66 DLTs 66 cytopenias 66 hypokalemia 66 TORISEL 66 delayed CINV 66 locoregional recurrence 66 hypersensitivity reactions 65 severe hypersensitivity reactions 65 oxycodone CR 65 #mg BID [001] 65 mg kg dose 65 ZYVOX 65 8mg/kg 65 plus dexamethasone 65 voriconazole 65 candidemia 65 symptomatic VTE 65 proctitis 65 Adverse events 65 piperacillin tazobactam 65 non hematological toxicities 65 Thrombocytopenia 65 neutropenia febrile neutropenia 65 mcg kg REBETOL 65 pegylated interferon alfa 2b 65 mg BID 65 BARACLUDE ® 65 solifenacin 65 ATACAND 65 grade cervical intraepithelial 65 placebo dexamethasone 65 invasive aspergillosis 65 FOLPI 65 patients receiving ERBITUX 65 octreotide LAR 65 Folfox 65 HBeAg negative 65 HBeAg seroconversion 65 CIMZIA TM 65 myalgia arthralgia 65 mcg BID 65 HBeAg positive patients 65 tirofiban 65 rFVIIa 65 TEAEs 65 HBeAg negative patients 65 NEUPOGEN 64 EXJADE 64 mg/m2 dose 64 recurrent genital herpes 64 p = NS 64 recurrent glioblastoma multiforme 64 plus 5-FU/LV 64 adjunctive placebo 64 certolizumab 64 thrombocytopenia anemia 64 teriflunomide 64 clodronate 64 mRCC 64 severe exacerbations 64 Peg IFN 64 hematological adverse 64 gout flares 64 PREZISTA r 64 idraparinux 64 hematological toxicity 64 Pred Forte 64 venous thromboembolic events 64 APTIVUS r 64 toxicities 64 invasive candidiasis 64 Dermatologic toxicities 64 CR nPR 64 lymphocytosis 64 elevated ALT 64 neutropenia anemia 64 ara C 64 partial remissions 64 haematologic 64 virologic failure 64 FOLFIRI 64 thromboembolic 64 external genital lesions 64 x ULN 64 composite endpoint 64 pleural effusion 64 MCyR 64 fluvastatin 64 transaminase elevations 64 posaconazole 64 Navelbine 64 dasatinib 64 Zometa hazard 64 lopinavir r 64 Erythropoietic therapies may 64 tolvaptan 64 QTc prolongation 64 dose cytarabine 64 highly emetogenic 64 transaminase elevation 63 severe hypoglycemic 63 myalgia 63 pyrexia 63 dose limiting toxicities 63 gastrointestinal perforation 63 hallucinations dyskinesia 63 evaluable subjects 63 mcg QD 63 tipranavir r 63 TMP SMX 63 mg QD 63 imipenem 63 hepatotoxicity 63 neutrophil counts 63 rizatriptan 63 pruritis 63 esophagitis 63 thrombotic events 63 dermatologic toxicities 63 hepatic encephalopathy 63 ribavirin therapy 63 definite stent thrombosis 63 % CI #.#-#.# [007] 63 locoregional 63 diarrhea nausea fatigue 63 metastatic GIST 63 FOLFOX6 63 relapsed MM 63 angioneurotic edema 63 vandetanib 63 placebo p = 63 plus methotrexate 63 recurrent venous thromboembolism 63 elotuzumab 63 cervical intraepithelial neoplasia 63 pruritus 63 CCyR 63 adriamycin 63 thromboembolism 63 acute GvHD 63 ribavirin RBV 63 IIIa inhibitor 63 alpha interferons 63 PROMACTA 63 ximelagatran 63 corticosteroid therapy 63 zolmitriptan 63 CHOP chemotherapy 63 bosentan 63 adalimumab 63 complete cytogenetic response 63 reinfarction 63 alfa 2a 63 ARCALYST ® 63 docetaxel chemotherapy 63 Amgen Neulasta R 63 COPD exacerbation 63 dose dexamethasone 63 amoxicillin clavulanate 63 alanine aminotransferase 63 hypotension 63 MACCE 63 neutropenic patients 63 bacteremia 63 COPD exacerbations 63 mg dose 63 squamous histology 63 splenectomized patients 63 mucosal inflammation 63 BENICAR HCT 63 generalized seizures 63 CMV infection 63 hematologic toxicities 63 tigecycline 62 hemoptysis 62 seropositive patients 62 esophageal candidiasis 62 renal insufficiency 62 serum urate 62 CLL SLL 62 immune thrombocytopenic purpura ITP 62 anemia neutropenia 62 thrombocytopenic 62 virologic response 62 virological failure 62 confidence interval CI 62 thrombophlebitis 62 AEs 62 TAXUS p value 62 HbA 1c levels 62 microbiological eradication 62 receiving INTRON 62 amphotericin B 62 cabazitaxel 62 azathioprine 62 zoledronic acid 62 hematological toxicities 62 ertapenem 62 myopathy rhabdomyolysis 62 vWD 62 hyperbilirubinemia 62 fatigue diarrhea nausea 62 asthenia 62 pancytopenia 62 TNF antagonist 62 ritonavir boosted 62 endometrial hyperplasia 62 mcg kg 62 VELCADE melphalan 62 receiving ISENTRESS 62 patients evaluable 62 doxorubicin docetaxel 62 mg ustekinumab 62 μg dose 62 stage IIIB 62 arthralgia 62 SPRYCEL ® 62 log# copies mL 62 mg/# h 62 XIENCE V PROMUS Stent 62 peginterferon alfa 2b 62 docetaxel Taxotere ® 62 NATRECOR ® 62 CINV 62 cisplatin chemotherapy 62 Doxil ® 62 vinorelbine 62 dacarbazine DTIC 62 CIMZIA ™ 62 ARCALYST 62 ULORIC 62 mycophenolate mofetil MMF 62 nadroparin 62 Pemetrexed 62 FOLFOX4 alone 62 canakinumab 62 basiliximab 62 spinal cord compression 62 aminotransferase elevations greater 62 prednisone prednisolone 62 P = .# 62 dose cohort 62 VFEND 62 abacavir lamivudine 62 HCV genotypes 62 refractory gout 62 levofloxacin 62 LEXIVA r 62 adverse reactions incidence 62 sensory neuropathy 62 TNF antagonists 62 discontinuations 62 VAPRISOL 62 MYCAMINE 62 ORENCIA 62 NATRECOR R 62 heparin induced thrombocytopenia 62 cerebrovascular events 62 Durezol 62 moderately emetogenic 62 Tarceva TM 62 non splenectomized 62 tapentadol ER 62 cytogenetic response 62 aldosterone antagonist 62 ALT elevation 62 hemorrhagic complications 62 leukemia AML 62 danazol 62 concomitant medications 62 hyperkalemia 62 YERVOY 62 limiting toxicity 62 biologic DMARD 62 binary restenosis 62 fluticasone salmeterol 62 hypersensitivity reaction 62 CANCIDAS 62 ABC/3TC 62 EBRT 62 interferon alfa 2b 62 refractory NSCLC 62 sustained virologic response 62 interferon alfa 62 CIMZIA TM certolizumab pegol 62 IXEMPRA 62 cutaneous squamous cell carcinoma 62 tipranavir 62 GEMZAR 62 azacitidine 62 pericardial effusion 62 hyperphenylalaninemia HPA due 62 metastatic malignant melanoma 62 cholecystitis 61 pneumonitis 61 micafungin 61 Pegasys ® 61 Epratuzumab 61 systemic corticosteroid 61 anemia hemoglobin 61 ug dose 61 evaluable 61 receiving XGEVA 61 infusional 5-FU/LV 61 ‰ ¥ 61 standard chemotherapy regimen 61 mg m² 61 deep venous thromboses 61 divalproex sodium 61 headache abdominal pain 61 Telintra 61 NOLVADEX 61 decitabine 61 chronic GVHD 61 pheochromocytoma 61 pruritus itching 61 Paraplatin ® 61 nonfatal MI 61 recurrent UTI 61 abciximab 61 Angioedema 61 pimecrolimus 61 daunorubicin 61 median PFS 61 #mg/m# [001] 61 oral vancomycin 61 PRADAXA 61 fluorouracil leucovorin 61 ARIXTRA 61 AST ALT 61 plus aztreonam 61 acute coronary syndromes ACS 61 graft dysfunction 61 CR CRu 61 tolterodine ER 61 Tindamax R 61 complement inhibitor eculizumab 61 steroid dexamethasone 61 receiving VELCADE 61 treatment naive genotype 61 mcg albinterferon alfa 2b 61 von Willebrand disease 61 renal toxicity 61 follicular lymphoma FL 61 antiemetics 61 bone marrow suppression 61 postoperative chemotherapy 61 Elitek 61 dacarbazine 61 MDS MPD 61 Navelbine ® 61 REMICADE ® 61 neutrophil count 61 ecchymosis 61 hepatorenal syndrome 61 chemotherapy induced neutropenia 61 grade glioma 61 Cutaneous T 61 ARCOXIA 61 adalimumab Humira 61 sternal wound infections 61 β blockers 61 calcineurin inhibitors 61 mg qd 61 Renal impairment 61 Vandetanib 61 forodesine 61 QTcF 61 doxorubicin cyclophosphamide 61 ruboxistaurin 61 neutropenic sepsis 61 ALT elevations 61 Myelosuppression 61 Adjuvant chemotherapy 61 thrombotic complications 61 arthralgias 61 virologic failures 61 systemic absorption 61 galiximab 61 dyspnea 61 metastatic malignant 61 platinum refractory 61 CIN3 61 ALVESCO 61 peginterferon alfa 61 virologic responses 61 DAPT 61 relapsed refractory multiple myeloma 61 humanized interleukin 6 61 small lymphocytic lymphoma 61 triamcinolone 61 immunosuppressive agents 61 conjunctival hyperemia 61 mg + GLY 61 Lupuzor ™ 61 baminercept 61 Hypotension 61 FASLODEX 61 linezolid 61 hemorrhagic cystitis 61 cilengitide 61 platelet reactivity 61 GOUT 61 antibiotic prophylaxis 61 ARB telmisartan 61 leukemia ALL 61 linaclotide treated 61 eplerenone 61 salmeterol fluticasone 61 pericardial effusions 61 HES CEL 61 xanthine oxidase inhibitor 61 oral levofloxacin 61 KRAS mutations occur 61 posterior uveitis 61 chemoradiotherapy 61 anakinra 61 Vfend 61 intravascular hemolysis 61 aspartate aminotransferase 61 splenectomized 61 nilotinib 61 generalized edema 61 adjunctive ABILIFY 61 Aptivus ® 61 chemoradiation therapy 61 ALT normalization 61 plus GP IIb 61 mg TID 61 achieved statistical significance 61 ACR# response 61 doxazosin 61 idarubicin 61 Noxafil 61 cobiprostone 61 rosuvastatin #mg 61 carboplatin paclitaxel 61 ethambutol 61 LAMICTAL 61 refractory ischemia 61 intravenous bisphosphonates 61 myelodysplastic myeloproliferative diseases 61 ocular adverse 61 cardiac toxicity 61 adefovir 61 idiopathic thrombocytopenic purpura 61 mitoxantrone plus 61 ACTEMRA 61 Free Survival PFS 61 BEACOPP 61 liposomal amphotericin B 61 CMV disease 61 prolonged QT interval 61 mCi kg 61 ceftriaxone 60 cisplatin vinorelbine 60 dasatinib Sprycel ® 60 interstitial lung disease 60 cyclophosphamide methotrexate 60 5FU 60 atherothrombotic events 60 pegylated interferon alfa 60 achieved PASI 60 Psoriasis Area 60 paresthesias 60 peritumoral brain edema 60 immunocompetent patients 60 virologic breakthrough 60 invasive fungal infections 60 aprepitant 60 MULTAQ 60 GnRH agonist 60 biochemical relapse 60 diarrhea nausea vomiting 60 intracranial hemorrhage ICH 60 #mg/m# [002] 60 superficial edema 60 dexamethasone Decadron 60 related hematological toxicity 60 pegIFN 60 MGd 60 Known hypersensitivity 60 fluconazole 60 complete remissions 60 Median PFS 60 MALT lymphoma 60 abatacept 60 % Confidence Interval 60 polycythemia vera essential thrombocythemia 60 hepatitis C genotype 60 EFFEXOR XR 60 TO AVOID PREGNANCY WHILE 60 recurrent DVT 60 grade cervical dysplasia 60 XELOX 60 angioedema 60 prophylaxis 60 PREZISTA rtv 60 hepatic failure 60 Pharmacokinetics PK 60 desvenlafaxine succinate 60 beclomethasone dipropionate 60 antimicrobial prophylaxis 60 Serious adverse reactions 60 Pegasys plus Copegus 60 GvHD 60 stage IIIb IV 60 oral diclofenac 60 paclitaxel cisplatin 60 anemia leukopenia 60 pCR 60 pertuzumab 60 metastatic lung cancer 60 Hematologic 60 LYSTEDA 60 REYATAZ r 60 certolizumab pegol 60 hypocalcemia 60 histologic subtype 60 EUFLEXXA R 60 PegIFN RBV 60 upper gastrointestinal bleeding 60 60 somnolence fatigue 60 extrapyramidal disorder 60 etanercept 60 primidone 60 morphometric vertebral fractures 60 Hycamtin ® 60 pegfilgrastim 60 macroalbuminuria 60 PRADAXA #mg 60 moderate renal impairment 60 plus OBT 60 interferon alfa 2a 60 acute GVHD 60 inflammatory lesions 60 nadolol 60 infliximab monotherapy 60 acute gout flares 60 immune thrombocytopenic purpura 60 valsartan amlodipine 60 Follicular Lymphoma 60 docetaxel Taxotere 60 Fluorouracil 60 distant metastasis 60 rebleeding 60 tipranavir ritonavir 60 sunitinib 60 receiving PEGINTRON 60 nonvertebral fractures 60 surgical prophylaxis 60 chills fever headache 60 potent CYP#A# inhibitors 60 Neulasta ® 60 PEGylated interferon beta 1a 60 TYKERB 60 AVELOX 60 gout flare 60 renal dysfunction 60 DMARDS 60 Kepivance 60 concomitant antibiotics 60 FUSILEV enhances 60 SVR# 60 XIENCE V vs. 60 mg/m2 60 BRIM2 60 oral Hycamtin 60 peginterferon 60 methotrexate monotherapy 60 Ribavirin causes 60 Median survival 60 low dose dexamethasone 60 intravenous vancomycin 60 aldosterone antagonists 60 aplastic anemia AA 60 delayed onset CINV 60 advanced adenoma 60 salmeterol HFA MDI 60 Peginterferon Alfa 2a 60 recurrent ischemia 60 myelodysplastic syndrome MDS 60 ACZ# 60 Engerix B 60 events SAEs 60 hepatic adverse 60 LPV r 60 LEXIVA 60 Pegylated Interferon 60 infusional 60 adefovir treated 60 OADs 60 acneform rash 60 Peginterferon alfa 2b 60 tamsulosin 60 anterior uveitis 60 mitomycin 60 RGT arm 60 pT3 60 PEGylated Fab fragment 60 anthracycline taxane 60 relapsed SCLC 60 azathioprine monotherapy 60 variceal bleeding 60 histologically confirmed 60 dapagliflozin plus 60 AA Amyloidosis 60 serum aminotransferase levels 60 chronic HCV infection 60 constipation nausea 60 gadobutrol 60 Peginterferon 60 nausea vomiting headache 60 FluCAM 60 PEGINTRON TM 60 unfavorable cytogenetics 60 INCB# [003] 60 perioperatively 60 malignancy HCM 60 pimecrolimus cream 60 MADRS score 60 gemcitabine carboplatin 60 Cimzia TM 60 superficial bladder cancer 60 pulmonary embolus 60 Thal Dex 60 treatment emergent AEs 60 gastrointestinal toxicity 60 cutaneous T 60 docetaxel Taxotere R 60 lamivudine 60 anemia nausea 60 mg m 60 bendamustine 60 PASI scores 60 HCV SPRINT 60 Mitoxantrone 60 mg BID dose 60 fondaparinux 60 lamivudine refractory patients 60 entecavir 60 adjuvant radiotherapy 60 benazepril 60 ipsilateral stroke 60 CTAP# Capsules 60 haematological toxicity 60 receiving golimumab 60 plus ribavirin 60 neurologic complications 60 dapsone 60 CIMZIA 60 pooled comparator 60 rhinorrhea 59 Copegus ribavirin 59 pegylated interferon alpha 59 ancrod 59 nevirapine Viramune 59 pyrazinamide 59 HBeAg positive 59 receiving highly emetogenic 59 Stent thrombosis 59 % CI #.#-#.# [003] 59 TYGACIL 59 elevated serum creatinine 59 serologically active patients 59 receptor tyrosine kinase inhibitor 59 dose interleukin 59 seroconversion 59 aspartate aminotransferase AST 59 VIIBRYD 59 vaccinees 59 #mg doses [002] 59 metabolic alkalosis 59 dexamethasone 59 contrast induced nephropathy 59 postoperative nausea 59 lenalidomide dexamethasone 59 TMC# r 59 adrenal suppression 59 severe renal impairment 59 BENICAR 59 mcg doses 59 TDF FTC 59 imatinib 59 liver transaminases 59 platelet counts 59 headache nausea diarrhea 59 lactic acidosis 59 alemtuzumab treated 59 cisplatin gemcitabine 59 dysuria 59 extrapyramidal symptoms 59 hydroxychloroquine 59 flutamide 59 smoldering multiple myeloma 59 Dasatinib 59 BYSTOLIC 59 Retreatment 59 PEGylated anti 59 sorafenib Nexavar 59 mcg mL 59 IV NSCLC 59 thrombolytic agents 59 ABVD 59 metastatic RCC 59 thromboembolic complications 59 severe rotavirus gastroenteritis 59 Natalizumab 59 symptomatic intracranial hemorrhage 59 peginterferon alfa 2a 59 tacrolimus ointment 59 microgram kg 59 ADHF 59 transaminases 59 COMBIVIR 59 Monotherapy 59 cytogenetic responses 59 tumor recurrence 59 rituximab refractory 59 VIDAZA 59 preoperative chemotherapy 59 pruritus rash 59 colorectal adenoma 59 proteinuria 59 intravesical therapy 59 Trastuzumab 59 CIN2 59 nicardipine 59 anaphylactoid reactions 59 ORENCIA ® 59 experienced hypomagnesemia 59 bevacizumab Avastin 59 salmeterol fluticasone propionate 59 oxymorphone ER 59 Relapsing Remitting Multiple Sclerosis 59 Pegasys peginterferon alfa 2a 59 serum phosphate 59 erythema redness 59 Bezielle 59 amprenavir 59 nucleoside naive patients 59 baseline HbA1c 59 unresectable HCC 59 Myelofibrosis 59 INVANZ 59 6R BH4 59 Fludarabine 59 platelet inhibitor 59 chronic eosinophilic leukemia 59 unresectable stage 59 enoxaparin 59 lenalidomide Revlimid R 59 SinuNase TM 59 pomalidomide 59 log# reduction 59 nonhematologic adverse reactions 59 iclaprim 59 clinically evaluable patients 59 PREMPRO 59 estramustine 59 DETROL LA 59 advanced hepatocellular carcinoma 59 FROVA 59 node metastases 59 curative resection 59 hypereosinophilic syndrome 59 dose cohorts 59 erythema 59 oral candidiasis 59 tamoxifen Nolvadex ® 59 titrated glipizide 59 evaluable patients 59 pegylated liposomal doxorubicin 59 adverse reactions irrespective 59 REVLIMID ® 59 Platinol ® 59 cell lymphoma CTCL 59 INTELENCE 59 saline placebo 59 HCV Genotype 59 corticosteroid dose 59 distant metastases 59 infliximab Remicade 59 nodular partial response 59 5 Fluorouracil 59 myelofibrosis polycythemia vera 59 Myelodysplastic Syndrome MDS 59 bevacizumab 59 mycosis fungoides 59 Xelox 59 oblimersen 59 interstitial pneumonia 59 azacytidine 59 follicular NHL 59 metastatic CRC 59 Venous thromboembolism 59 bortezomib 59 palifermin 59 ELOXATIN 59 Castration Resistant Prostate Cancer 59 lopinavir ritonavir Kaletra 59 β blocker 59 tocilizumab 59 calcineurin inhibitor 59 SUVmax 59 advanced adenomas 59 efavirenz EFV 59 epithelial tumors 59 interferon ribavirin 59 Lupus nephritis 59 HBeAg 59 invasive fungal infection 59 RLAI 59 SGPT 59 melphalan prednisone 59 unresectable 59 KETEK 59 heavily pretreated 59 cough dyspnea 59 SAEs 59 vertebral fracture 59 romiplostim 59 sulfasalazine 59 investigational monoclonal antibody 59 Pegylated Liposomal Doxorubicin 59 Capecitabine 59 icatibant 59 Diffuse Large B 59 adverse reactions observed 59 atazanavir 59 monotherapy 59 NNT = 59 log# IU mL 59 grade dysplasia 59 Lactic acidosis 59 overt nephropathy 59 brivaracetam 59 ritonavir boosted lopinavir 59 bradycardia 59 stage IIIb 59 insulin detemir 59 urinary retention 59 PAOD 59 CsA 59 mcg dose 59 dermatologic reactions 59 alpha 2a 59 visilizumab 59 doripenem 59 TAXOTERE ® 59 HPV-#/# 59 symptomatic intracranial 59 events TEAEs 59 Postoperative complications 59 #mg QD [001] 59 serum potassium 59 lupus nephritis 59 INVEGA ® 59 Vaprisol 59 #mg dose [003] 59 receiving prophylactic anticoagulation 59 rilonacept 59 placebo p 59 Sezary syndrome 59 sorafenib tablets 59 imiquimod 59 antiarrhythmic drugs 59 dose colchicine 59 Candida infections 59 ropivacaine 59 RBC transfusions 59 LVEF 59 postvaccination 59 cilostazol 59 HIV HCV coinfected 59 grade gliomas 59 Response Evaluation Criteria 59 Telithromycin 59 efalizumab 59 PSA nadir 59 Thrombotic events 59 basal cell carcinoma BCC 59 hematologic adverse reactions 59 LOVENOX 59 beta blocker therapy 59 Hazard Ratio 59 REVLIMID R 59 Index CDAI 59 serum HBV DNA 59 hematologic abnormalities 59 HCV RESPOND 2 59 Traficet EN 59 Elotuzumab 59 mycophenolate 59 purpura ITP 58 HSCT 58 Gemzar ® 58 topotecan 58 OAB symptoms 58 symptomatic hypotension 58 PEG Interferon alfa 58 Adalimumab 58 steroid refractory ulcerative 58 erlotinib Tarceva ® 58 gastric adenocarcinoma 58 mitomycin C 58 myeloproliferative diseases 58 chills fatigue 58 mapatumumab 58 REYATAZ 58 lichen planus 58 gemifloxacin 58 oral antidiabetic medication 58 liver decompensation 58 pegaptanib 58 epirubicin 58 chemoradiation 58 nab paclitaxel 58 KRAS mutant tumors 58 PRECiSE 58 Refractory Hodgkin Lymphoma 58 ketoconazole 58 dysplastic lesions 58 peripheral neuropathy aggravated 58 chlorthalidone 58 liver histology 58 argatroban 58 aspirin heparin 58 refractory AML

Back to home page